Current developments in thrombolytic therapy using novel plasminogen activators.
As a result of intensive recent research, the molecular mechanisms governing the human fibrinolytic system could be elucidated. Clinical trials using streptokinase and urokinase demonstrated that therapeutic thrombolysis is a valuable regimen in the treatment of patients with thromboembolic diseases. After unsuccessful attempts to increase the clot specificity of these agents, efforts were increased towards developing fibrin-specific substances with high thrombolytic potency and negligible effects on systemic hemostasis. Tissue-type plasminogen activator manufactured by recombinant DNA technology (rt-PA) is currently the most comprehensively investigated fibrin-specific thrombolytic agent with the most clearly understood mechanism of action in vivo. Pro-urokinase has also become available through biotechnology. A large number of clinical trials studying thrombolytic therapy of myocardial infarction have proved that intravenous rt-PA posesses superior efficacy compared to conventional fibrinolytic agents. Comparatively few clinical studies have been performed using pro-urokinase. At therapeutic doses, the fibrin specificities of these agents differ. So far it has not been possible to correlate the incidence of bleeding complications during fibrinolytic therapy with alterations in hemostasis parameters. For routine laboratory monitoring of thrombolysis the determination of fibrinogen and thrombin clotting time can be recommended. New developments with potential for yielding the next generation of thrombolytic agents are mutants and chimeras of t-PA and pro-urokinase, and conjugates of these substances with fibrin specific antibodies.
Seifried
E
E
Abteilung Innere Medizin III, Medizinische Klinik und Poliklinik der Universität Ulm, Fed. Rep. of Germany.
Tanswell
P
P
D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D010960:Plasminogen Activators / Q000494:pharmacology / Q000627:therapeutic use*; D013923:Thromboembolism / Q000188:drug therapy* / Q000503:physiopathology
D005343:Fibrinolytic Agents; D010960:Plasminogen Activators